search
Back to results

Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain

Primary Purpose

Pain, Chronic

Status
Withdrawn
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Phenol Injection
Methylprednisolone Injection
Sponsored by
Northwestern University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Chronic focused on measuring Total knee arthroplasty, Chronic Pain

Eligibility Criteria

40 Years - 95 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Ages 40-95 years
  • Patients with knee pain, on average > 4 (NRS) persisting more than 6 months after TKA
  • Willingness to undergo image guided diagnostic nerve block and the study intervention

Exclusion Criteria:

  • Pain score (NRS) < 4 at time of study enrollment
  • Conditions that preclude the diagnostic block or the study intervention (e.g., irreversible coagulopathy or bleeding disorder, allergic reaction/contraindication to local anesthetic, contrast dye, steroids, and/or phenol, pregnancy, severe or uncontrolled medical illness).
  • Evidence of indolent infection of the knee prosthesis (elevated C-reactive protein assessed when clinically indicated)
  • Inability to write, speak, or read in English
  • Pregnancy

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Other

    Arm Label

    Treatment Group: Phenol injection

    Control Group: Methylprednisolone injection

    Arm Description

    6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target sites

    Methylprednisolone acetate 10 mg with 2 mL preservative free saline and 0.5 mL iopamidol 300 will be injected at each of the target site

    Outcomes

    Primary Outcome Measures

    Oxford Knee Score
    Oxford Knee Score is a tool which measures 6 post operative items (pain,flexion contracture, extension lag, total range of flexion, alignment of varus and valgus,stability (antero-posterior and mediolateral). The scoring is: below 60 is poor, scoring 60-69 fair, scoring 70-79 good, 80-100 excellent.

    Secondary Outcome Measures

    Numeric Rating Scale Score
    The proportion of subjects who have > 50% reduction in pain based on the Numeric Rating Scale at 3 months. The NRS is a scale of 0 (no pain) to 10 (worst pain imaginable)
    Numeric Rating Scale Score
    The proportion of subjects who have > 50% reduction in pain based on the Numeric Rating Scale at 6 months. The NRS is a scale of 0 (no pain) to 10 (worst pain imaginable)
    Patients Global Impression of Change
    Patients Global Impression of Change (GPIC) is a scale of 0 (much better) to 10 (much worse)
    Patients Global Impression of Change
    Patients Global Impression of Change (GPIC) is a scale of 0 (much better) to 10 (much worse)
    Opioid analgesic use at 3 months
    Opioid analgesic daily use by self reporting .
    Opioid analgesic use at 6 months
    Opioid analgesic daily use by self reporting.
    Non-opioid analgesic use at 3 months
    Non opioid analgesic daily use by self reporting.
    Non-opioid analgesic use at 6 months
    Non opioid analgesic daily use by self reporting.
    PROMIS Pain Intensity Short Form 3a
    3 question pain survey. 5 responses (had no pain),(mild), (moderate), (severe) and (very severe)
    PROMIS Pain Intensity Short Form 3a
    3 question pain survey. 5 responses (had no pain),(mild), (moderate), (severe) and (very severe)
    PROMIS Pain Intensity Short Form 3a
    3 question pain survey. 5 responses (had no pain),(mild), (moderate), (severe) and (very severe)
    PROMIS Sleep Disturbance Short Form 4a
    4 question sleep survey. First section is quality of sleep rated on a 5 response (very poor)- (very good) scale.Section rating quality of sleep based on 5 response choices (not at all) to (very much)
    PROMIS Sleep Disturbance Short Form 4a
    4 question sleep survey. First section is quality of sleep rated on a 5 response (very poor)- (very good) scale.Section rating quality of sleep based on 5 response choices (not at all) to (very much)
    PROMIS Sleep Disturbance Short Form 4a
    4 question sleep survey. First section is quality of sleep rated on a 5 response (very poor)- (very good) scale.Section rating quality of sleep based on 5 response choices (not at all) to (very much)
    PROMIS Pain Interference Short Form 6b
    6 question pain survey. First section is interference of pain rated on a 5 response (not at all)- (very much) scale. Section is one socialization question with 5 response choices (never)- (always)
    PROMIS Pain Interference Short Form 6b
    6 question pain survey. First section is interference of pain rated on a 5 response (not at all)- (very much) scale. Section is one socialization question with 5 response choices (never)- (always)
    PROMIS Pain Interference Short Form 6b
    6 question pain survey. First section is interference of pain rated on a 5 response (not at all)- (very much) scale. Section is one socialization question with 5 response choices (never)- (always)
    Oxford Knee Score
    12 question survey with 5 choice responses based on severity of pain while accomplishing activities of daily living.
    Oxford Knee Score
    12 question survey with 5 choice responses based on severity of pain while accomplishing activities of daily living.
    Hospital Anxiety and Depression Scale
    Hospital Anxiety and Depression Scale (HADS) is a 14 question survey (7 anxiety and 7 depression) questions answered on a 0 (low) - 3 (high) scale.Total score of 0-7 is normal, 8-10 is baseline abnormal and a score between 11-21 is abnormal.
    Hospital Anxiety and Depression Scale
    Hospital Anxiety and Depression Scale (HADS) is a 14 question survey (7 anxiety and 7 depression) questions answered on a 0 (low) - 3 (high) scale.Total score of 0-7 is normal, 8-10 is baseline abnormal and a score between 11-21 is abnormal.
    Hospital Anxiety and Depression Scale
    Hospital Anxiety and Depression Scale (HADS) is a 14 question survey (7 anxiety and 7 depression) questions answered on a 0 (low) - 3 (high) scale. Total score of 0-7 is normal, 8-10 is baseline abnormal and a score between 11-21 is abnormal.

    Full Information

    First Posted
    May 28, 2019
    Last Updated
    April 20, 2022
    Sponsor
    Northwestern University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03973177
    Brief Title
    Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain
    Official Title
    Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain Following Total Knee Arthroplasty: a Pilot Prospective, Randomized, Crossover Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2022
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Covid restrictions on recruitment
    Study Start Date
    May 24, 2019 (Actual)
    Primary Completion Date
    July 2022 (Anticipated)
    Study Completion Date
    March 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Northwestern University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Chronic knee pain from osteoarthritis (OA) is commonly treated with total knee arthroplasty (TKA) when conservative therapies fail to provide pain relief. More than 600,000 TKAs are performed in the U.S. annually, a number that continues to increase. A logistic-regression model suggests that the incidence rate of TKA will increase by 143% in the United States by 2050 compared to 2012. Although TKA is successful in reducing knee pain and joint stiffness in most cases, it can be associated with a 7-35% incidence of persistent refractory post-surgical knee pain. Aim: To determine whether chemical neurolysis of the genicular nerves with 6% aqueous phenol is non-inferior in reducing knee pain as compared to corticosteroid injection of the genicular nerves, in patients with refractory chronic knee pain for more than 6 months after total knee replacement. Hypothesis: Chemical neurolysis of genicular nerves with phenol will provide equal or superior pain relief than corticosteroid genicular nerve injections at 3 months, as measured by the Oxford Knee Score.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pain, Chronic
    Keywords
    Total knee arthroplasty, Chronic Pain

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Crossover Assignment
    Model Description
    A Pilot Prospective, Randomized, Crossover Trial. (Block randomization scheme with 2:1 allocation (phenol neurolysis : perineural steroid injection) The crossover will occur in subjects who received the steroid injection who did not achieve adequate pain relief at 3 months.
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Treatment Group: Phenol injection
    Arm Type
    Experimental
    Arm Description
    6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target sites
    Arm Title
    Control Group: Methylprednisolone injection
    Arm Type
    Other
    Arm Description
    Methylprednisolone acetate 10 mg with 2 mL preservative free saline and 0.5 mL iopamidol 300 will be injected at each of the target site
    Intervention Type
    Drug
    Intervention Name(s)
    Phenol Injection
    Other Intervention Name(s)
    Phenol
    Intervention Description
    6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target site with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged phenol covering the lateral margin of the femur or tibia respectively on AP and lateral views. The needles will then be removed and band-aids placed.
    Intervention Type
    Drug
    Intervention Name(s)
    Methylprednisolone Injection
    Other Intervention Name(s)
    Methylprednisolone acetate
    Intervention Description
    Methylprednisolone acetate 10 mg with 2 mL preservative saline and 0.5 mL iopamidol 300 will be injected at each of the 3 target sites with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged steroid mixture covering the lateral margin of the femur or tibia respectively on AP and lateral views; the needles will be removed and band-aids placed.
    Primary Outcome Measure Information:
    Title
    Oxford Knee Score
    Description
    Oxford Knee Score is a tool which measures 6 post operative items (pain,flexion contracture, extension lag, total range of flexion, alignment of varus and valgus,stability (antero-posterior and mediolateral). The scoring is: below 60 is poor, scoring 60-69 fair, scoring 70-79 good, 80-100 excellent.
    Time Frame
    3 months
    Secondary Outcome Measure Information:
    Title
    Numeric Rating Scale Score
    Description
    The proportion of subjects who have > 50% reduction in pain based on the Numeric Rating Scale at 3 months. The NRS is a scale of 0 (no pain) to 10 (worst pain imaginable)
    Time Frame
    3months
    Title
    Numeric Rating Scale Score
    Description
    The proportion of subjects who have > 50% reduction in pain based on the Numeric Rating Scale at 6 months. The NRS is a scale of 0 (no pain) to 10 (worst pain imaginable)
    Time Frame
    6 months
    Title
    Patients Global Impression of Change
    Description
    Patients Global Impression of Change (GPIC) is a scale of 0 (much better) to 10 (much worse)
    Time Frame
    3 Months
    Title
    Patients Global Impression of Change
    Description
    Patients Global Impression of Change (GPIC) is a scale of 0 (much better) to 10 (much worse)
    Time Frame
    6 Months
    Title
    Opioid analgesic use at 3 months
    Description
    Opioid analgesic daily use by self reporting .
    Time Frame
    3 months
    Title
    Opioid analgesic use at 6 months
    Description
    Opioid analgesic daily use by self reporting.
    Time Frame
    6 months
    Title
    Non-opioid analgesic use at 3 months
    Description
    Non opioid analgesic daily use by self reporting.
    Time Frame
    3 Months
    Title
    Non-opioid analgesic use at 6 months
    Description
    Non opioid analgesic daily use by self reporting.
    Time Frame
    6 Months
    Title
    PROMIS Pain Intensity Short Form 3a
    Description
    3 question pain survey. 5 responses (had no pain),(mild), (moderate), (severe) and (very severe)
    Time Frame
    Baseline
    Title
    PROMIS Pain Intensity Short Form 3a
    Description
    3 question pain survey. 5 responses (had no pain),(mild), (moderate), (severe) and (very severe)
    Time Frame
    3 Months
    Title
    PROMIS Pain Intensity Short Form 3a
    Description
    3 question pain survey. 5 responses (had no pain),(mild), (moderate), (severe) and (very severe)
    Time Frame
    6 Months
    Title
    PROMIS Sleep Disturbance Short Form 4a
    Description
    4 question sleep survey. First section is quality of sleep rated on a 5 response (very poor)- (very good) scale.Section rating quality of sleep based on 5 response choices (not at all) to (very much)
    Time Frame
    Baseline
    Title
    PROMIS Sleep Disturbance Short Form 4a
    Description
    4 question sleep survey. First section is quality of sleep rated on a 5 response (very poor)- (very good) scale.Section rating quality of sleep based on 5 response choices (not at all) to (very much)
    Time Frame
    3 Months
    Title
    PROMIS Sleep Disturbance Short Form 4a
    Description
    4 question sleep survey. First section is quality of sleep rated on a 5 response (very poor)- (very good) scale.Section rating quality of sleep based on 5 response choices (not at all) to (very much)
    Time Frame
    6 Months
    Title
    PROMIS Pain Interference Short Form 6b
    Description
    6 question pain survey. First section is interference of pain rated on a 5 response (not at all)- (very much) scale. Section is one socialization question with 5 response choices (never)- (always)
    Time Frame
    Baseline
    Title
    PROMIS Pain Interference Short Form 6b
    Description
    6 question pain survey. First section is interference of pain rated on a 5 response (not at all)- (very much) scale. Section is one socialization question with 5 response choices (never)- (always)
    Time Frame
    3 Months
    Title
    PROMIS Pain Interference Short Form 6b
    Description
    6 question pain survey. First section is interference of pain rated on a 5 response (not at all)- (very much) scale. Section is one socialization question with 5 response choices (never)- (always)
    Time Frame
    6 Months
    Title
    Oxford Knee Score
    Description
    12 question survey with 5 choice responses based on severity of pain while accomplishing activities of daily living.
    Time Frame
    Baseline
    Title
    Oxford Knee Score
    Description
    12 question survey with 5 choice responses based on severity of pain while accomplishing activities of daily living.
    Time Frame
    6 Months
    Title
    Hospital Anxiety and Depression Scale
    Description
    Hospital Anxiety and Depression Scale (HADS) is a 14 question survey (7 anxiety and 7 depression) questions answered on a 0 (low) - 3 (high) scale.Total score of 0-7 is normal, 8-10 is baseline abnormal and a score between 11-21 is abnormal.
    Time Frame
    Baseline
    Title
    Hospital Anxiety and Depression Scale
    Description
    Hospital Anxiety and Depression Scale (HADS) is a 14 question survey (7 anxiety and 7 depression) questions answered on a 0 (low) - 3 (high) scale.Total score of 0-7 is normal, 8-10 is baseline abnormal and a score between 11-21 is abnormal.
    Time Frame
    3 Month
    Title
    Hospital Anxiety and Depression Scale
    Description
    Hospital Anxiety and Depression Scale (HADS) is a 14 question survey (7 anxiety and 7 depression) questions answered on a 0 (low) - 3 (high) scale. Total score of 0-7 is normal, 8-10 is baseline abnormal and a score between 11-21 is abnormal.
    Time Frame
    6 Month

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    40 Years
    Maximum Age & Unit of Time
    95 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Ages 40-95 years Patients with knee pain, on average > 4 (NRS) persisting more than 6 months after TKA Willingness to undergo image guided diagnostic nerve block and the study intervention Exclusion Criteria: Pain score (NRS) < 4 at time of study enrollment Conditions that preclude the diagnostic block or the study intervention (e.g., irreversible coagulopathy or bleeding disorder, allergic reaction/contraindication to local anesthetic, contrast dye, steroids, and/or phenol, pregnancy, severe or uncontrolled medical illness). Evidence of indolent infection of the knee prosthesis (elevated C-reactive protein assessed when clinically indicated) Inability to write, speak, or read in English Pregnancy
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    David Walega, MD
    Organizational Affiliation
    Northwestern University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    22147711
    Citation
    Nguyen US, Zhang Y, Zhu Y, Niu J, Zhang B, Felson DT. Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data. Ann Intern Med. 2011 Dec 6;155(11):725-32. doi: 10.7326/0003-4819-155-11-201112060-00004.
    Results Reference
    background
    PubMed Identifier
    25917518
    Citation
    Buvanendran A, Fiala J, Patel KA, Golden AD, Moric M, Kroin JS. The Incidence and Severity of Postoperative Pain following Inpatient Surgery. Pain Med. 2015 Dec;16(12):2277-83. doi: 10.1111/pme.12751. Epub 2015 Apr 27.
    Results Reference
    background
    PubMed Identifier
    25542191
    Citation
    Lewis GN, Rice DA, McNair PJ, Kluger M. Predictors of persistent pain after total knee arthroplasty: a systematic review and meta-analysis. Br J Anaesth. 2015 Apr;114(4):551-61. doi: 10.1093/bja/aeu441. Epub 2014 Dec 26.
    Results Reference
    background
    PubMed Identifier
    26301182
    Citation
    Drosos GI, Triantafilidou T, Ververidis A, Agelopoulou C, Vogiatzaki T, Kazakos K. Persistent post-surgical pain and neuropathic pain after total knee replacement. World J Orthop. 2015 Aug 18;6(7):528-36. doi: 10.5312/wjo.v6.i7.528. eCollection 2015 Aug 18.
    Results Reference
    background
    PubMed Identifier
    20299989
    Citation
    Puolakka PA, Rorarius MG, Roviola M, Puolakka TJ, Nordhausen K, Lindgren L. Persistent pain following knee arthroplasty. Eur J Anaesthesiol. 2010 May;27(5):455-60. doi: 10.1097/EJA.0b013e328335b31c.
    Results Reference
    background
    PubMed Identifier
    18627367
    Citation
    Fischer HB, Simanski CJ, Sharp C, Bonnet F, Camu F, Neugebauer EA, Rawal N, Joshi GP, Schug SA, Kehlet H; PROSPECT Working Group. A procedure-specific systematic review and consensus recommendations for postoperative analgesia following total knee arthroplasty. Anaesthesia. 2008 Oct;63(10):1105-23. doi: 10.1111/j.1365-2044.2008.05565.x. Epub 2008 Jul 10.
    Results Reference
    background
    PubMed Identifier
    28801208
    Citation
    Inacio MCS, Paxton EW, Graves SE, Namba RS, Nemes S. Projected increase in total knee arthroplasty in the United States - an alternative projection model. Osteoarthritis Cartilage. 2017 Nov;25(11):1797-1803. doi: 10.1016/j.joca.2017.07.022. Epub 2017 Aug 8.
    Results Reference
    background
    PubMed Identifier
    28697032
    Citation
    Sylvester LN, Goree JH. Genicular Radiofrequency Ablation for Treatment of Post Total Knee Arthroplasty Posterior Thigh Pain: A Case Report. A A Case Rep. 2017 Nov 15;9(10):292-293. doi: 10.1213/XAA.0000000000000596.
    Results Reference
    background
    PubMed Identifier
    27641918
    Citation
    Qudsi-Sinclair S, Borras-Rubio E, Abellan-Guillen JF, Padilla Del Rey ML, Ruiz-Merino G. A Comparison of Genicular Nerve Treatment Using Either Radiofrequency or Analgesic Block with Corticosteroid for Pain after a Total Knee Arthroplasty: A Double-Blind, Randomized Clinical Study. Pain Pract. 2017 Jun;17(5):578-588. doi: 10.1111/papr.12481. Epub 2016 Sep 19.
    Results Reference
    background
    PubMed Identifier
    24373908
    Citation
    Protzman NM, Gyi J, Malhotra AD, Kooch JE. Examining the feasibility of radiofrequency treatment for chronic knee pain after total knee arthroplasty. PM R. 2014 Apr;6(4):373-6. doi: 10.1016/j.pmrj.2013.10.003. Epub 2013 Dec 27.
    Results Reference
    background
    PubMed Identifier
    29514315
    Citation
    Walega DR, McCormick ZL. Chemical Neurolysis of the Genicular Nerves for Chronic Knee Pain: Reviving an Old Dog and an Old Trick. Pain Med. 2018 Sep 1;19(9):1882-1884. doi: 10.1093/pm/pny023. No abstract available.
    Results Reference
    background
    PubMed Identifier
    27228515
    Citation
    Koyyalagunta D, Engle MP, Yu J, Feng L, Novy DM. The Effectiveness of Alcohol Versus Phenol Based Splanchnic Nerve Neurolysis for the Treatment of Intra-Abdominal Cancer Pain. Pain Physician. 2016 May;19(4):281-92.
    Results Reference
    background
    PubMed Identifier
    17151902
    Citation
    Wang PJ, Shang MY, Qian Z, Shao CW, Wang JH, Zhao XH. CT-guided percutaneous neurolytic celiac plexus block technique. Abdom Imaging. 2006 Nov-Dec;31(6):710-8. doi: 10.1007/s00261-006-9153-5.
    Results Reference
    background
    PubMed Identifier
    9862538
    Citation
    Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil. 1998 Nov-Dec;77(6):510-5. doi: 10.1097/00002060-199811000-00012.
    Results Reference
    background
    PubMed Identifier
    27867513
    Citation
    Ahmed A, Arora D, Kochhar AK. Ultrasound-guided alcohol neurolysis of lateral femoral cutaneous nerve for intractable meralgia paresthetica: a case series. Br J Pain. 2016 Nov;10(4):232-237. doi: 10.1177/2049463716668811. Epub 2016 Sep 16.
    Results Reference
    background

    Learn more about this trial

    Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain

    We'll reach out to this number within 24 hrs